

REPORT TO THE LEGISLATURE
Pursuant to P.A. 119 of 2023
Article 2, Section 607
MAT Clinics
FY24 – 1st Quarter

Sec. 607 (2) The department must submit quarterly reports on the status of establishment and operation of medication assisted treatment clinics. Reports shall include, but not be limited to, all of the following:

- (a) Site locations selected.
- (b) Staffing levels.
- (c) Expenditures on staffing and supplies, including oral and injectable medications.
- (d) Number of prisoners treated.
- (e) Number of prisoners requiring treatment but not yet receiving treatment.

Michigan Department of Corrections currently has all 27 correctional facilities prescribing naltrexone and 10 of those correctional facilities are currently prescribing buprenorphine products for Medications for Assisted Treatment (MAT) for those diagnosed with an Opioid Use Disorder. MDOC will expand buprenorphine products to three more correctional facilities starting in March of 2024 for a total of 13 correctional facilities offering buprenorphine. The information below is for the first quarter of FY24 which will be updated on the quarter 2 report as we do not have all the expenses for December due to pending invoices.

Site locations selected	Buprenorphine Sites	10
	Naltrexone Sites	26
	New MAT sites established	0
Staffing levels	Filled MAT Positions	14
	Vacant MAT Positions	4
Expenditures on staffing	State of Michigan:	\$50,160.06
	Temp:	\$253,845.14
	TOTAL COST:	<u>\$304,005.20</u>
Expenditures on supplies, including oral and injectable medications	*Sublocade:	\$412,353.06
	Suboxone:	\$14,342.53
	Naltrexone:	\$19,238.82
	TOTAL COST:	<u>\$445,934.41</u>
	<i>(\$2.5 million dollars were used from the Opioid Settlement Fund to pay for Sublocade in Q1)</i>	
Number of prisoners treated	Number of inmates that have received at least 1 dose of MAT medication	
	TOTAL:	<u>1,496</u>
Number of prisoners requiring treatment but not yet receiving treatment		TOTAL: <u>2,554</u>